نتائج البحث - "левосимендан"

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 20, № 3 (2023); 84-93 ; Вестник анестезиологии и реаниматологии; Том 20, № 3 (2023); 84-93 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: артериальная гипотония, levosimendan, multiple organ failure syndrome, shock, arterial hypotension, левосимендан, синдром полиорганной недостаточности, шок

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/819/643; Беллетти А., Аццолини М. Л., Балдетти Л. и др. Применение инотропных препаратов и вазопрессоров в реаниматологии и периоперационной медицине: доказательный подход (обзор) // Общая реаниматология. – 2022. – Т.18, № 5. – С. 60–77. Doi:10.15360/1813-9779-2022-5-60-77.; Еременко А. А. Медикаментозное лечение острой сердечной недостаточности: что есть и что нас ждет // Вестник анестезиологии и реаниматологии. – 2020. – Т. 17, № 2. – С. 29–37. Doi:10.21292/2078-5658-2020-17-2-29-3.; Кочкин А. А., Яворовский А. Г., Берикашвили Л. Б. и др. Современная вазопрессорная терапия септического шока (обзор) // Общая реаниматология. – 2020. – Т.16, № 2. – С. 77–93. Doi:10.15360/1813-9779-2020-2-77-93.; Bravo M. C., López P., Cabañas F. et al. Acute effects of levosimendan on cerebral and systemic perfusion and oxygenation in newborns: an observational study // Neonatology – 2011. – Vol. 99, № 3. – P. 217–223. Doi:10.1159/000314955.; Cleland J. G., Freemantle N., Coletta A. P. et al. Clinical trials update from the American Heart Association // REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROAC TIVE // Eur. J. Heart Fail. – 2006. – № 8. – P. 105–110. Doi:10.1016/j.ejheart.2005.12.003.; Colucci W. S, Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments // N Engl J Med. – 1986. – Vol. 314. – P. 290–299. Doi:10.1056/NEJM198602063140605.; Das B. B., Moskowitz W. B., Butler J. Current and future drug and device therapies for pediatric heart failure patients // Potential Lessons from Adult Trials. – 2021. – Vol. 8, № 5. – Р. 322. Doi:10.3390/children8050322. PMID: 33922085; PMCID: PMC8143500.; Dellinger R. M., Rhodes A. D., Gerlach H. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012 // Intensive Care Medicine. – 2013. – Vol. 39, № 2. – Р. 165–228. Doi:10.1097/CCM.0b013e31827e83af.; Elsherbini H., Soliman O., Zijderhand C. et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients // Heart Fail Rev. – 2022. – Vol. 27, № 2. – Р. 493–505. Doi:10.1007/s10741-021-10101-0.; Esch J., Joynt C., Manouchehri N. et al. Differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation // Neonatology. – 2012. – Vol. 101, № 3. – Р. 192–200. Doi:10.1159/000329825.10.; Evans L., Rhodes A., Alhazzani W. at al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021// Intensive Care Med. – 2021. – Vol. 47, № 11. – Р. 1181–1247. Doi:10.1007/s00134-021-06506-y.; Fang M., Cao H., Wang Z. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis // Med Intensiva (Engl Ed). – 2018. – Vol. 42, № 7. – Р. 409–415. Doi:10.1016/j.medin.2017.08.009.; Feng F., Chen Y., Li M. et al. Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis // Chin Med J (Engl). – 2019. – Vol. 132, № 10. – Р. 1212–1217. Doi:10.1097/CM9.0000000000000197.; Giordano R., Cantinotti M., Mannacio V. A. et al. First Experience WithLevosimendan Therapy After Correction of Congenital Heart Disease // J CardiothoracVascAnesth. – 2017. – Vol. 31, № 1. – Р. 19–21. Doi:10.1053/j.jvca.2016.08.017.; Guarracino F., Heringlake M., Cholley B. et al. Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice // J Cardiovasc Pharmacol. – 2018. – Vol. 71, № 1. – Р. 1–9. Doi:10.1097/FJC.0000000000000551.; Häberle H. A. Levosimendan – a 20-Year Experience // Anasthesiol Intensivmed Notfallmed Schmerzther. – 2021. – Vol. 56, № 6. – Р. 414–426. Doi:10.1055/a-1214-4485.; Hummel J., Rücker G., Stiller B. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease // Cochrane Database Syst Rev. – 2017. – Vol. 8, № 8. – CD011312. Doi:10.1002/14651858.; Jaguszewski M. J., Gasecka A., Targonski R. et al. Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis // Cardiol J. – 2021. – Vol. 28, № 3. – Р. 492–493. Doi:10.5603/CJ.a2021.0037.; Joynt C., Cheung P. Y. Cardiovascular Supportive Therapies for Neonates With Asphyxia – A Literature Review of Pre-clinical and Clinical Studies // Front Pediatr. – 2018. – № 6. – Р. 363. Doi:10.3389/fped.2018.00363.; Karami M., Hemradj V. V., Ouweneel D. M. et al. Vasopressors and inotropes in acute myocardial infarction related cardiogenic shock: a systematic review and meta-analysis // J ClinMed. – 2020. – Vol. 9, № 7. – Р. 2051. Doi:10.3390/jcm9072051.; Lapere M., Rega F., Rex S. Levosimendan in paediatric cardiac anaesthesiology: A systematic review and meta-analysis // Eur J Anaesthesiol. – 2022. – Vol. 39, № 8. – Р. 646–655. Doi:10.1097/EJA.0000000000001711.; Liu K., Wang H., Yu S. J. et al. Inhaled pulmonary vasodilators: a narrative review // AnnTranslMed. – 2021. – Vol. 9, № 7. – Р. 597. Doi:10.21037/atm-20-4895.; Liu D. H., Ning Y. L., Lei Y. Y. et al. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis // Sci Rep. – 2021. – Vol. 11, № 1. – Р. 20333. Doi:10.1038/s41598-021-99716-9.; Loss K. L., Shaddy R. E., Kantor P. F. Recent and upcoming drug therapies for pediatric heart failure // Front Pediatr. – 2021. – Vol. 11, № 9. – Р. 681224. Doi:10.3389/fped.2021.681224.; Miller L. E., Laughon M. M., Clark R. H. et al. Vasoactive medications in extremely low gestational age neonates during the first postnatal week // J Perinatol. – 2021. – Vol. 41, № 9. – Р. 2330–2336. Doi:10.1038/s41372-021-01031-8.; Morelli A., De Castro S., Teboul J. L. et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression // Intensive Care Med. – 2005. – № 31. – Р. 638–644. Doi:10.1007/s00134-005-2619-z.; Nieminen M. S., Buerke M., Cohen-Solál A. et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion // Int. J. Cardiol. – 2016. – № 218. – Р. 150–157. Doi:10.1016/j.ijcard.2016.05.009.; Nieminen M. S., Fruhwald S., Heunks L. M. A. et al. Levosimendan: current data, clinical use and future development // Heart Lung Vessel. – 2013. – Vol. 5, № 4. – P. 227–245. PMID: 24364017.; Papp Z., Agostoni P., Alvarez J. et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use // Card Fail Rev. – 2020. – № 6. – Р. e19. Doi:10.15420/cfr.2020.03.; Ponikowski P., Voors A. A., Anker S. D. et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC // Eur Heart J. – 2016. – Vol. 37, № 27. – Р. 2129–2200. Doi:10.1093/eurheartj/ehw128.; Raasmaja A., Talo A., Haikala H. et al. Biochemical properties of OR-1259: a positive inotropic and vasodilatory compound with an antiarrhythmic effect // Adv Exp Med Biol. – 1992. – № 311. – Р. 423. Doi:10.1007/978-14615-3362-7_63.; Rhodes A., Evans L. E., Alhazzani W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 // Crit. Care Med. – 2017. – Vol. 45, № 3. – Р. 486–552. Doi:10.1007/s00134-017-4683-6.; Ricci Z., Garisto C., Favia I. et al. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial // Intensive Care Med. – 2012. – Vol. 38, № 7. – Р. 1198–1204. Doi:10.1007/s00134-012-2564-6.; Santillo E., Migale M., Massini C., et al. Levosimendan for Perioperative Cardioprotection: Myth or Reality? // Curr. Cardiol Rev. – 2018. – Vol. 14, № 3. – P. 142–152. Doi:10.2174/1573403X14666180322104015.; Schumann J., Henrich E. C., Strobl H. et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome // Cochrane Database Syst Rev. – 2018. – Vol. 1, № 1. – CD009669. Doi:10.1002/14651858.; Schwarza C. E., Dempseya E. M. Management of Neonatal Hypotension and Shock // Seminars in Fetal and Neonatal Medicine. – 2020. – № 25. – Р. 1–7. Doi:10.1016/j.siny.2020.101121.; Sharma D. Golden hour of neonatal life: need of the hour // Matern Health Neonatol Perinatol. – 2017. – Vol. 19, № 3. – Р. 16. Doi:10.1186/s40748-017-0057-x.; Silvetti S., Silvani P., Azzolini M. L. et al. A systematic review on Levosimendan in paediatric patients // Curr Vasc Pharmacol. – 2015. – Vol. 13, № 1. – Р. 128–33. Doi:10.2174/1570161112666141127163536.; Silvetti S., Belletti A., Bianzina S. et al. Effect of Levosimendan treatment in pediatric patients with cardiac dysfunction: an update of a systematic review and meta-analysis of randomized controlled trials // J. CardiothoracVasc Anesth. – 2022. – Vol. 36, № 3. – Р. 657–664. Doi:10.1053/j.jvca.2021.09.018.; Singh Y., Katheria A. C., Vora F. Advances in diagnosis and management of hemodynamic instability in neonatal shock // Front Pediatr. – 2018. – Vol. 6, № 2. Doi:10.3389/fped.2018.00002.; Tumminello G., Cereda A., Barbieri L. et al. Meta-analysis of placebo-controlled trials of levosimendan in acute myocardial infarction // J Cardiovasc Dev Dis. – 2021. – Vol. 8, № 10. – Р. 129. Doi:10.3390/jcdd8100129.; Uhlig K., Efremov L., Tongers J., et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome // Cochrane Database Syst Rev. – 2020. – Vol. 11, № 11. – CD009669. Doi:10.1002/14651858.; Unverzagt S., Wachsmuth L., Hirsch K. et al. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome // Cochrane Database Syst Rev. – 2014. – № 1. – CD009669. Doi:10.1002/14651858.; Van Diepen S., Katz J. N., Albert N. M. et al. Contemporary management of cardiogenic shock: a scientific statement from the american heart association // Circulation. – 2017. – Vol. 136, № 16. – Р. e232–e268. Doi:10.1161/CIR.0000000000000525.; Weber C., Esser M., Eghbalzadeh K., et al. Levosimendan reduces mortality and low cardiac output syndrome in cardiac surgery // Thorac Cardiovasc Surg. – 2020. – Vol. 68, № 5. – Р. 401–409. Doi:10.1055/s-0039-3400496.; Weisert M., Su J. A., Menteer J. et al. Drug treatment of heart failure in children: gaps and opportunities // Paediatr Drugs. – 2022. – Vol. 24, № 2. – Р. 121–136. Doi:10.1007/s40272-021-00485-9.; Zhou S., Zhang L., Li J. Effect of levosimendan in patients with acute decompensated heart failure: A meta-analysis // Herz. – 2019. – Vol. 44, № 7. – Р. 630–636. Doi:10.1007/s00059-018-4693-3.; https://www.vair-journal.com/jour/article/view/819

الاتاحة: https://www.vair-journal.com/jour/article/view/819
https://doi.org/10.24884/2078-5658-2023-20-3-84-93

View record in BASE

4

Academic Journal

Levosimendan Hemodynamic Effects Depending on the Outcome of Sepsis ; Гемодинамические эффекты левосимендана в зависимости от исхода сепсиса

المؤلفون: I. N. Tyurin, D. N. Protsenko, I. A. Kozlov, И. Н. Тюрин, Д. Н. Проценко, И. А. Козлов

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 19, № 4 (2022); 31-43 ; Вестник анестезиологии и реаниматологии; Том 19, № 4 (2022); 31-43 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: инотропные препараты, septic shock, septic cardiomyopathy, levosimendan, inotropic drugs, септический шок, септическая кардиомиопатия, левосимендан

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/693/577; Баутин А. Е., Ксендикова А. В., Белолипецкий С. С. и др. О возможности использования фармакологических индексов для прогнозирования течения послеоперационного периода кардиохирургических вмешательств // Вестник интенсивной терапии им. А. И. Салтанова. – 2019. – № 2. – С. 66–74. doi:10.21320/1818-474X-2019-2-66-74.; Козлов И. А., Тюрин И. Н., Раутбарт С. А. Ранние гемодинамические предикторы летального исхода абдоминального сепсиса // Вестник анестезиологии и реаниматологии. ‒ 2018. – Т. 15, № 2. – С. 6–15. doi.org/10. 21292/2078-5658-2018-15-2-6-15.; Кузьков В. В., Киров М. Ю. Инвазивный мониторинг гемодинамики в интенсивной терапии и анестезиологи. 2-е изд. Архангельск: Северный государственный медицинский университет. ‒ 2015. ‒ С. 392. ISBN 978-591702-180-5.; Ломиворотов В. В., Бобошко В. А. Плейотропные эффекты левосимендана на сердце и другие органы // Патология кровообращения и кардиохирургия. – 2017. – Т. 21, № 2. – С. 14‒28. doi.org/10.21688/1681-3472-2017-2-14-28.; Тюрин И. Н., Раутбарт С. А., Проценко Д. Н. и др. Биомаркер напряжения миокарда NT-proBNP у больных с абдоминальным сепсисом и септическим шоком // Патология кровообращения и кардиохирургия. – 2020. – Т. 24, № 1. – С. 65‒77. doi:10.21688/1681-3472-2020-1-65-77.; Angus D. C., van der Poll T. Severe sepsis and septic shock // N. Engl. J. Med. – 2013. – Vol. 369. – № 9. – P. 840–851. doi:10.1056/NEJMra1208623.; Belletti A., Benedetto U., Biondi-Zoccai G. et al. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials // J. Crit. Care. – 2017. – Vol. 37. – P. 91–98. doi:10.1016/j.jcrc.2016.08.010.; Belletti A., Castro M. L., Silvetti S. et al. The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials // Br. J. Anaesth. – 2015. – Vol. 115, № 5. – P. 656‒675. doi:10.1093/bja/aev284.; Bhattacharjee S., Soni K. D., Maitra S. et al. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials // J. Clin. Anesth. – 2017. – Vol. 39. – P. 67–72. doi:10.1016/j.jclinane.2017.03.011.; Burkhoff D., Rich S., Pollesello P. et al. Levosimendan-induced venodilation is mediated by opening of potassium channels // ESC Heart Fail. ‒ 2021. – Vol. 8, № 6. – P. 4454‒4464. doi:10.1002/ehf2.13669.; Chang W., Xie J. F., Xu J. Y. et al. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials // BMJ Open. ‒ 2018. – Vol. 8. – № 3. – P. e019338. doi:10.1136/bmjopen-2017-019338.; Conti N., Gatti M., Raschi E. et al. Evidence and current use of levosimendan in the treatment of heart failure: filling the gap // Drug Des. Devel. Ther. – 2021. – Vol. 15. – P. 3391‒3409. doi:10.2147/DDDT.S295214.; Cunha G. J. L., Rocha B. M. L., Gomes R. V. et al. Levosimendan with other inotropes or vasopressors: Should you combine them? // Am. J. Emerg. Med. ‒ 2020. – Vol. 38, № 12. – P. 2723‒2726. doi:10.1016/j.ajem.2020.03.059.; Dabrowski W., Siwicka-Gieroba D., Piasek E. et al. Successful combination of landiolol and levosimendan in patients with decompensated heart failure // Int. Heart J. – 2020. – Vol. 61, № 2. – P. 384‒389. doi:10.1536/ihj.19-420.; Evans L., Rhodes A., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 // Crit. Care Med. 2021. – Vol. 49, № 11. – P. e1063‒e1143. doi:10.1097/CCM.0000000000005337.; Frommeyer G., Kohnke A., Ellermann C. et al. Experimental evidence for a severe proarrhythmic potential of levosimendan // Int. J. Cardiol. ‒ 2017. – Vol. 228. – P. 583‒587. doi:10.1016/j.ijcard.2016.11.251.; Glinka L., Mayzner-Zawadzka E., Onichimowski D. et al. Levosimendan in the modern treatment of patients with acute heart failure of various aetiologies // Arch. Med. Sci. ‒ 2019. – Vol. 17, № 2. – P. 296‒303. doi:10.5114/aoms.2018.77055.; Gordon A. C., Perkins G. D., Singer M. et al. Levosimendan for the prevention of acute organ dysfunction in sepsis // N. Engl. J. Med. ‒ 2016. – Vol. 375, № 17. – P. 1638‒1648. doi:10.1056/NEJMoa1609409.; Hobai I. A., Edgecomb J., LaBarge K. et al. Dysregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathy // Shock. – 2015. – Vol. 43, № 1. – P. 3–15. doi:10.1097/SHK.0000000000000261.; Hollenberg S. M., Singer M. Pathophysiology of sepsis-induced cardiomyopathy // Nat. Rev. Cardiol. ‒ 2021. – Vol. 18, № 6. – P. 424‒434. doi:10.1038/s41569-020-00492-2.; Kakoullis L., Giannopoulou E., Papachristodoulou E. et al. The utility of brain natriuretic peptides in septic shock as markers for mortality and cardiac dysfunction: a systematic review // Int. J. Clin. Pract. ‒ 2019. – Vol. 73, № 7. – P. e13374. https://doi.org/10.1111/ijcp.13374.; Kumar A., Krieger A., Symeoneides S. et al. Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide // J. Cardiothorac. Vasc. Anesth. – 2001. – Vol. 15, № 4. – P. 485–511. doI:10.1053/jcan.2001.25003.; Liu D. H., Ning Y. L., Lei Y. Y. et al. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis // Sci. Rep. ‒ 2021. – Vol. 11, № 1. – P. 20333. doi:10.1038/s41598-021-99716-9.; Morelli A., De Castro S., Teboul J. L. et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression // Int. Care Med. – 2005. – Vol. 31, № 5. – P. 638‒644. doi:10.1007/s00134-005-2619-z.; Nandhabalan P., Ioannou N., Meadows C. et al. Refractory septic shock: our pragmatic approach // Crit Care. – 2018. – Vol. 22, № 1. – P. 215. doi:10.1186/s13054-018-2144-4. PMID: 30231909.; Nieminen M. S., Fruhwald S., Heunks L. M. et al. Levosimendan: current data, clinical use and future development // Heart Lung Vessel. – 2013. – Vol. 5, № 4. – P. 227‒245. PMID: 24364017 PMCID: PMC3868185.; Pathak A., Lebrin M., Vaccaro A. et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects // J. Clin. Pharm. Ther. – 2013. – Vol. 38, № 5. – P. 341‒349. doi:10.1111/jcpt.12067.; Pierrakos C., Velissaris D., Franchi F. et al. Levosimendan in critical illness: a literature review // J. Clin. Med. Res. 2014. – Vol. 6, № 2. – P. 75‒85. doi:10.14740/jocmr1702w.; Pinto B. B., Rehberg S., Ertmer C. et al. Role of levosimendan in sepsis and septic shock // Curr. Opin. Anaesthesiol. – 2008. – Vol. 21, № 2. – P. 168‒177. doi:10.1097/ACO.0b013e3282f43c56.; Ravikumar N., Sayed M. A., Poonsuph C. J. et al. Septic cardiomyopathy: from basics to management choices // Curr. Probl. Cardiol. ‒ 2021. – Vol. 46, № 4. – P. 100767. doi:10.1016/j.cpcardiol.2020.100767.; Rhodes A., Evans L. E., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016 // Int. Care Med. – 2017. – Vol. 43, № 3. – P. 304‒377. doi:10.1007/s00134-017-4683-6.; Sato R., Ariyoshi N., Hasegawa D. et al. Effects of inotropes on the mortality in patients with septic shock // J. Int. Care Med. – 2021. – Vol. 36, № 2. – P. 211‒219. doi:10.1177/0885066619892218.; Scheeren T. W. L., Bakker J., Kaufmann T. et al. Current use of inotropes in circulatory shock // Ann. Int. Care. – 2021. – Vol. 11, № 1. – P. 21. doi:10.1186/s13613-021-00806-8.; Sepsis: Recognition, Assessment and Early Management. National Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK); 2016 Jul. – PMID: 27441326.; Singer M., Deutschman C. S., Seymour C. W. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) // JAMA. – 2016. – Vol. 315, № 8. – P. 801‒810. doi:10.1001/jama.2016.0287. PMID: 26903338.; Torraco A., Carrozzo R., Piemonte F. et al. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial // Biochimie. – 2014. – Vol. 102. – P. 166‒173. doi:10.1016/j.biochi.2014.03.006.; Wang J., Wang X. T., Liu D. W. et al. Induction and deduction in sepsis-induced cardiomyopathy: five typical categories // Chin. Med. J. (Engl.). – 2020. – Vol. 133, № 18. – P. 2205‒2211. doi:10.1097/CM9.0000000000000929.; Werdan K., Oelke A., Hettwer S. et al. Septic cardiomyopathy: hemodynamic quantification, occurrence, and prognostic implications // Clin. Res. Cardiol. – 2011. – Vol. 100, № 8. – P. 661–668. doi:10.1007/s00392-011-0292-5.; Wilkman E., Kaukonen K. M., Pettilä V. et al. Association between inotrope treatment and 90-day mortality in patients with septic shock // Acta Anaesthesiol. Scand. 2013. – Vol. 57, № 4. – P. 431‒442. doi:10.1111/aas.12056.; Zangrillo A., Putzu A., Monaco F. et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials // J. Crit. Care. – 2015. – Vol. 30, № 5. – P. 908‒913. doi:10.1016/j.jcrc.2015.05.017.; Zhang Y., Khalid S., Jiang L. Diagnostic and predictive performance of biomarkers in patients with sepsis in an intensive care unit // J. Int. Med. Res. ‒2019. – Vol. 47, № 1. – P. 44‒58. https://doi.org/10.1177/0300060518793791.; Zorn-Pauly K., Pelzmann B., Lang P. et al. Endotoxin impairs the human pacemaker current If // Shock. – 2007. – Vol. 28, № 6. – P. 655–661. PMID: 18092381.; https://www.vair-journal.com/jour/article/view/693

الاتاحة: https://www.vair-journal.com/jour/article/view/693
https://doi.org/10.21292/2078-5658-2022-19-4-31-43

View record in BASE

5

Academic Journal

The Use of Levosimendan in the Treatment of Neurogenic Stress Cardiomyopathy in a Patient with Nontraumatic Subarachnoid Hemorrhage (Case Report) ; Использование левосимендана при лечении нейрогенной стрессорной кардиомиопатии у пациентки с субарахноидальным кровоизлиянием (клиническое наблюдение)

المصدر: General Reanimatology; Том 17, № 4 (2021); 22-28 ; Общая реаниматология; Том 17, № 4 (2021); 22-28 ; 2411-7110 ; 1813-9779

مصطلحات موضوعية: нейрогенный отек легких, subarachnoid hemorrhage, levosimendan, neurogenic pulmonary edema, субарахноидальное кровоизлияние, левосимендан

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/2099/1532; https://www.reanimatology.com/rmt/article/view/2099/1533; Zaroﬀ J.G., Rordorf G.A., Ogilvy C.S., Picard M.H. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. J Am Soc Echocardiogr. 2000; 13: 774–779. DOI:10.1067/mje.2000.105763; Naidech A.M., Kreiter K.T., Janjua N., Ostapkovich N.D., Parra A., Commichau C., Fitzsimmons B-F.M., Connolly E.S., Mayer S.A. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. 2005; 112: 2851–2856. DOI:10.1067/mje.2000.105763; Bybee K.A., Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008; 118 (4): 397–409. DOI:10.1161/circulationaha.106.677625; Elrifai A.M., Bailes J.E., Shih S.R., Dianzumba S., Brillman J. Characterization of the car- diac eﬀects of acute subarachnoid hemorrhage in dogs. Stroke. 1996; 27: 737–741. DOI:10.1161/01.str.27.4.737; Lyon A.R., Rees P.S., Prasad S., Poole-Wilson P.A., Harding S.E. Stress (takotsubo) cardiomyopathy a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008; 5: 22–29. DOI:10.1038/ncpcardio1066; Baroldi G., Mittleman R.E., Parolini M., Silver M.D., Fineschi V. Myocardial contraction bands. Deﬁnition, quantiﬁcation and signiﬁcance in forensic pathology. Int J Legal Med. 2001; 115: 142–151. PMID: 11775016 DOI:10.1007/s004140100229; Grad A., Kiauta T., Osredkar J. Eﬀect of elevated plasma norepinephrine on electro- cardiographic changes in subarachnoid hemorrhage. Stroke. 1991; 22: 746–749. DOI:10.1161/01.str.22.6.746; Busani S., Rinaldi L., Severino C., Cobelli M., Pasetto A., Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. J Trauma. 2010; 68: E108–10. DOI:10.1097/ta.0b013e31817c4284; Papanikolaou J., Tsolaki V., Makris D., Zakynthinos E. Early levosimendan administration may improve outcome in patients with subarachnoid hemorrhage complicated by acute heart failure. Int J Cardiol. 2014; 176 (3): 1435–1437. DOI:10.1016/j.ijcard.2014.08.039; Taccone F.S., Brasseur A., Vincent J.L., De Backer D. Levosimendan for the treatment of subarachnoid hemorrhage-related cardiogenic shock. Inensive Care Med. 2013; 39 (8): 1497–1498. DOI:10.1007/s00134-013-2945-5; Papp Z., Agostoni P., Alvarez J., Bettex D., Bouchez S., Brito D., Černý V., Comin-Colet J., Crespo-Leiro M.G., Delgado J.F., Édes I., Eremenko A.A., Farmakis D., Fedele F., Fonseca C., Fruhwald S., Girardis M., Guarracino F., Harjola V.-P., Heringlake M., Herpain A., Heunks L.M.A., Husebye T., Ivancan V., Karason K., Kaul S., Kivikko M., Kubica J., Masip J., Matskeplishvili S., Mebazaa A., Nieminen M.S., Oliva F., Papp J.G., Parissis J., Parkhomenko A., Põder P., Pölzl G., Reinecke A., Ricksten S.-E., Riha H., Rudiger A., Sarapohja T., Schwinger R.H.G., Toller W., Tritapepe L., Tschöpe C., Wikström G., von Lewinski D., Vrtovec B., Pollesello P. Levosimendan Eﬃcacy and Safety: 20 Years of SIMDAX in Clinical Use. Cardiovasc Pharmacol. 2020; 76 (1): 4–22. DOI:10.1097/FJC.0000000000000859; https://www.reanimatology.com/rmt/article/view/2099

الاتاحة: https://www.reanimatology.com/rmt/article/view/2099
https://doi.org/10.15360/1813-9779-2021-4-22-28

View record in BASE

6

Academic Journal

ПРИМЕНЕНИЕ ЛЕВОСИМЕНДАНА В ПЕРИОПЕРАЦИОННОМ ПЕРИОДЕ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ ПРИ АОРТОКОРОНАРНОМ ШУНТИРОВАНИИ

المؤلفون: B. М. Тоdurov, М. V. Khartanovich, М. Rotari, Yu. V. Volkova, К. G. Мikhnevich, К. Yu. Sharlay

المصدر: Клінічна хірургія, Iss 12, Pp 5-8 (2017)

مصطلحات موضوعية: острый коронарный синдром, аортокоронарное шунтирование, маркеры повреждения миокарда, левосимендан, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://hirurgiya.com.ua/index.php/journal/article/view/295; https://doaj.org/toc/0023-2130; https://doaj.org/toc/2522-1396

URL الوصول: https://doaj.org/article/15391dc91a164e62934a8e17e94d7eed

View record in DOAJ

7

Academic Journal

Pleiotropic effects of levosimendan on the heart and other organs

المؤلفون: V. V. Lomivorotov, V. A. Boboshko

المصدر: Патология кровообращения и кардиохирургия, Vol 21, Iss 2, Pp 14-28 (2017)

مصطلحات موضوعية: левосимендан, плейотропные эффекты, кардиотонические препараты, сердечная недостаточность, инфаркт миокарда, кардиогенный шок, кардиопротекция, органопротекция, Surgery, RD1-811

وصف الملف: electronic resource

Relation: http://journalmeshalkin.ru/index.php/heartjournal/article/view/449; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/524bc0001bb646f89a1bbe615fb9be54

View record in DOAJ

8

Academic Journal

MAIN TENDENCIES IN ANESTHESIOLOGY DEVELOPMENT FOR THE LAST 10 YEARS ; ОСНОВНЫЕ ТЕНДЕНЦИИ РАЗВИТИЯ АНЕСТЕЗИОЛОГИИ ЗА ПОСЛЕДНИЕ 10 ЛЕТ

المؤلفون: V. V. Likhvantsev, В. В. Лихванцев

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 16, № 2 (2019); 25-33 ; Вестник анестезиологии и реаниматологии; Том 16, № 2 (2019); 25-33 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: анестетическое прекондиционирование, peri-operative period, dextrans. albumin, cardiac failure, levosimendan, anesthetic preconditioning, периоперационный период, декстраны, альбумин, сердечная недостаточность, левосимендан

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/316/338; Лихванцев В. В. Ингаляционная индукция и поддержание анестезии. ‒ М.: МИА, 2013. ‒ 320 с.; Лихванцев В. В. Инфузионная терапия в периоперационном периоде // Вестник анестезиологии и реаниматологии. – 2016. – Т. 13, № 5. – С. 66‒74.; Лихванцев В. В., Гребенчиков О. А., Борисов К. Ю. и др. Общие анестетики: определение и механизм действия // Медицинский алфавит: неотложная медицина – 2013. ‒ № 3. ‒ С. 18‒24.; Лихванцев В. В., Гребенчиков О. А., Шмелёва Е. А. и др. Анестетическое прекондиционирование: почему данные, полученные в эксперименте, не всегда подтверждаются в клинике? // Вестник анестезиологии и реаниматологии. ‒ 2013. ‒ Т. 10, № 4. ‒ С. 9‒14.; Лихванцев В. В., Мороз В. В., Гребенчиков О. А. и др. Ишемическое и фармакологическое прекондиционирование // Общая реаниматология. ‒ 2012. ‒ Т. VIII, № 1. ‒ С. 61‒66.; Лихванцев В. В., Ломиворотов В. В., Марченко Д. Н. и др. Предоперационная профилактика сердечной недостаточности в некардиальной хирургии // Общая реаниматология. ‒ 2016. ‒ Т. 11, № 3 ‒ С. 61‒69. DOI: http://dx.doi.org/10.15360/1813-9779-2016-3.; Лихванцев В. В. Анестезия, анальгезия, ноцицепция ‒ как совместить теорию и практику? Комментарий к статье А. Е. Карелова, К. М. Лебединского, В. И. Буравцова «Анестетик, анальгетик, гипнотик ‒ важны ли термины?» // Вестник анестезиологии и реаниматологии. – 2015. ‒ Т. 12, № 5. ‒ С. 11‒15.; Шевченко Ю. Л., Гороховатский Ю. И., Азизова О. А. и др. Севофлуран в кардиохирургии // Кардиология и сердечно-сосудистая хирургия. ‒ 2009. ‒ Т. 2, № 2. ‒ С. 58‒65.; Afshari A., De Hert S. Pitfalls of clinical practice guidelines in the era of broken science // Eur. J. Anaesthesiol. – 2018. – Vol. 35. – P. 903–906.; Brunkhorst F. M., Engel C., Bloos F. et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis // N. Engl. J. Med. ‒ 2008. – Vol. 358. – P. 125–139.; Cason B. A., Gamperl A. K., Slocum R. E. et al. Anesthetic-induced precondicioning: previous administration of isoflurane decreases myocardial infarct size in rabbits // Anesthesiology. ‒ 1997. ‒ Vol. 87. ‒ P. 1182‒1190.; Cholley B., Caruba T., Grosjean S. et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: The LICORN Randomized Clinical Trial // JAMA. – 2017. – Vol. 318. – P. 548‒556.; de Backer D., Donadello K., Taccone F. S. et al. Microcirculatory alterations: potential mechanisms and implications for therapy // Ann. Intens. Care. – 2011. – Vol. 1. ‒ Р. 27.; de Hert S. Cardioprotection by volatile anesthetics: What about noncardiac surgery? // J. Cardiothorac. Vasc. Anesth. – 2011. – Vol. 25. – P. 899–901.; de Hert S., Moerman A. Anesthetic preconditioning: have we found the holy grail of perioperative cardioprotection? // J. Cardioth. Vascular Anesthesia. – 2018. – Vol. 32, № 3. – P. 1135–1136.; de Hert S. G., Turani F., Mathur S. et al. Cardioprotection with volatile anesthetics: mechanisms and clinical implications // Anesth. Analg. ‒ 2005. ‒ Vol. 100. ‒ P.1584–1593.; du Toit E. F., Genis A., Opie L. H. et al. A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart // Br. J. Pharmacol. – 2014. – Vol. 154. – P. 41–50.; Eriksson O., Pollesello P., Haikala H. Effect of levosimendan on balance between ATP production and consumption in isolated perfused guinea-pig heart before ischemia or after reperfusion // J. Cardiovasc. Pharmacol. – 2004. – Vol. 44. – P. 316–321.; Ferdinandy P., Schulz R., Baxter G.T. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning // Pharmacol. Rev. ‒ 2007. ‒ Vol. 59. ‒ P. 418–458.; Finfer S., Bellomo R., Boyce N. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit // N. Engl. J. Med. – 2004. – Vol. 350. – P. 2247–2256.; Graham R., Mancher M., Miller Wolman D. et al. Clinical practice guidelines we can trust, Institute of Medicine Committee on standards for developing trustworthy clinical practice guidelines. Washington, DC, USA: National Academies Press. 2011.; Guidet B., Martinet O., Boulain T. et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study // Crit. Care. – 2012. ‒ Vol. 16. ‒ Р. 464.; Higgins J. P. T., Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011; [Updated March 2011]. Available from http://handbook.cochrane.org.; https://en.oxforddictionaries.com/definition/anaesthesiology.; https://www.britannica.com/science/anesthesiology.; Hydroxyethyl-starch solutions for infusion to be suspended – CMDh endorses PRAC recommendation [Internet] (Accessed 25 November 2018). Available from: https://www.ema.europa.eu/news/hydroxyethyl-starchsolutions-infusion-be-suspended-cmdh-endorses-prac-recommendation.; Jamali I. N., Kersten J. R., Pagel P. S. et al. Intracoronary levosimendan enhances contractile function of stunned myocardium // Anesth. Analg. – 1997. – Vol. 85. – P. 23–29.; Jiang L., Jiang S., Zhang M. et al. Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis // PLoS One. – 2014. – Vol. 9. ‒ Р. e114666.; Kristensen S. D., Knuuti J., Saraste A. et al. ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) // Eur. J. Anaesthesiol. – 2014. – Vol. 31, № 10. – P. 517‒573.; Landoni G., Augoustides J. G., Guarracino F. et al. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference // Acta Anaesth. Scand. – 2011. – Vol. 55. – P. 259‒266.; Landoni G., Lomivorotov V. V., Alvaro G. et al. Levosimendan for hemodynamic support after cardiac surgery // N. Engl. J. Med. – 2017. – Vol. 376. – P. 2021‒2031.; Lepran I., Pollesello P., Vajda S. et al. Preconditioning effects of evosimendan in a rabbit cardiac ischemia-reperfusion model // J. Cardiovasc. Pharmacol. – 2006. – Vol. 48. – P. 148–152.; Levijoki J., Pollesello P., Kaheinen P. et al. Improved survival with simendan after experimental myocardial infarction in rats // Eur. J. Pharmacol. – 2001. – Vol. 419. – P. 243–248.; Martin C., Cortegiani A., Gregoretti C. Choice of fluids in critically ill patients // BMC Anesthesiology. ‒ 2018. – Vol. 18. ‒ Р. 200.; Marx G., Schindler A. W., Mosch C. et al. Intravascular volume therapy in adults // Eur. J. Anaesthesiol. – 2016. – Vol. 33. – P. 1–34.; Mehta R. H., Leimberger J. D., van Diepen S. et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery // N. Engl. J. Med. – 2017. – Vol. 376. – P. 2032‒2042.; Messina A., Greco M., Cecconi M. Fluids in shock. Fluid management during shock from physiology to bedside // ICU managment and practice. – 2018. ‒ Vol. 18, № 3. ‒ P. 233‒240.; Moher D., Liberati A., Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement // BMJ. ‒ 2009. – Vol. 339. ‒ Р. b2535.; Murry C. E., Jennings R. B., Reimer K. A. Precondicioning with ischemia: a delay of lethal cell injury in ischemic myocardium // Circulation. ‒ 1986. ‒ Vol. 74. ‒ P. 1124–1136.; Myburgh J. A., Finfer S., Bellomo R. et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care // N. Engl. J. Med. – 2012. – Vol. 367. – P. 1901–1911.; Myburgh J. A., Mythen M. G. Resuscitation Fluids // N. Engl. J. Med. – 2013. – Vol. 369. – P. 1243–1251.; Niven D. J., McCormick T. J, Straus S. E. et al. Reproducibility of clinical research in critical care: a scoping review // BMC Med. – 2018. ‒ Vol. 16, № 26. – Р. 124‒132.; Patel A., Laffan M. A., Waheed U. et al. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality // BMJ. – 2014. – Vol. 349. ‒ Р. g4561.; Perel P., Roberts I., Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients // Cochrane Database Syst Rev. – 2011. – Vol. 16, № 3. ‒ CD000567.; Perner A., Haase N., Guttormsen A. B. et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis // N. Engl. J. Med. – 2012. ‒ Vol. 367. – P. 124–134.; Scheingraber S., Rehm M., Sehmisch C. et al. Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery // Anesthesiology. – 1999. –Vol. 90. – P. 1265–1270.; Schindler A. W., Marx G. Evidence-based fluid management in the ICU // Curr. Opin. Anaesthesiol. – 2016. – Vol. 29. – P. 158–165.; Shaneyfelt T. M., Centor R. M. Reassessment of clinical practice guidelines: go gently into that good night // JAMA. – 2009. – Vol. 301. – P. 868–869.; Shin C. H., Long D. R., McLean D. et al. Effects of intraoperative fluid management on postoperative outcomes: a hospital registry study // Ann. Surg. – 2018. – Vol. 267. – P. 1084–1092.; Sniderman A. D., Furberg C. D. Why guideline-making requires reform // JAMA. – 2009. – Vol. 301. – P. 429–431.; Thacker J. K. M., Mountford W. K., Ernst F. R. et al. Perioperative fluid utilization variability and association with outcomes: considerations for enhanced recovery efforts in sample US surgical populations // Ann. Surg. – 2016. – Vol. 263. – P. 502–510.; Toller W., Heringlake M., Guarracino F. et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion // Int. J. Cardiology. – 2015. ‒ Vol. 184. – P. 323–336.; Von Heymann C., Sander M., Spies C. D. Protocols, physiology, and trials of hydroxyethyl starch // N. Engl. J. Med. – 2012. – Vol. 367. – P. 1265–1267.; Weber N. C., Precker B., Shlack W. The effect of anesthetics on the myocardium – new insights into protection // Europ. J. Anest. ‒ 2005. ‒ Vol. 22, № 9. ‒ P. 647‒657.; Wiedermann C. J., Eisendle K. Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European medicines agency // J. Pharm. Policy Pract. – 2017. ‒ Vol. 10, № 12. ‒ P. 64‒68.; Woodcock T. E., Woodcock T. M. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy // Brit. J. Anaesthesia. – 2012. ‒ Vol. 108, № 3. – P. 384–394.; Xu J.-Y., Chen Q.-H., Xie J.-F. et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials // Crit. Care. – 2014. – Vol. 18. – P. 702‒712.; Yunos N., Bellomo R., Glassford N. Chlorideliberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis // Int. Care Med. ‒ 2015. – Vol. 41. – P. 257–264.; Yunos N. M., Bellomo R., Hegarty C. et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults // JAMA. ‒ 2012. ‒ Vol. 308. – P. 1566–1572.; Zangrillo A., Alvaro G., Belletti A. et al. Effect of Levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: a substudy of a multicenter randomized trial // J. Cardioth. Vasc. Anesthesia. – 2018. ‒ Vol. 32. – P. 2152‒2159.; https://www.vair-journal.com/jour/article/view/316

الاتاحة: https://www.vair-journal.com/jour/article/view/316
https://doi.org/10.21292/2078-5658-2019-16-2-25-33

View record in BASE

9

Academic Journal

On the possibility to increase sensitivity of diagnostic tests for fixed pulmonary hypertension in heart transplant candidates ; О возможности повышения информативности диагностики необратимой легочной гипертензии у кандидатов на трансплантацию сердца

المؤلفون: Bortsova M.A., Bautin A.E., Yakovlev A.S., Fedotov P.A., Sazonova Y.V., Marichev A.O., Tashkhanov D.M., Sukhova I.V., Vizer R.V., Moiseeva O.M., Sitnikova M.Y., Gordeev M.L.

المصدر: Almanac of Clinical Medicine; Vol 47, No 3 (2019); 212-220 ; Альманах клинической медицины; Vol 47, No 3 (2019); 212-220 ; 2587-9294 ; 2072-0505

مصطلحات موضوعية: heart transplantation, pulmonary hypertension, right heart catheterization, pulmonary vasoreactivity test, levosimendan, трансплантация сердца, легочная гипертензия, катетеризация легочной артерии, тест на обратимость легочной гипертензии, левосимендан

وصف الملف: application/pdf

الاتاحة: https://almclinmed.ru/jour/article/view/1066
https://doi.org/10.18786/2072-0505-2019-47-030

View record in BASE

10

Academic Journal

Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью

المصدر: Качественная клиническая практика, Vol 0, Iss 1 (2018)

مصطلحات موضوعية: фармакоэкономика, левосимендан, хроническая сердечная недостаточность, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/321; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/4edb5bc6db18490e84cba0e10d61e933

View record in DOAJ

11

Academic Journal

Influence of different nature cardiotonic medicines on the cytokine system of failing myocardium atthe pressure overload conditions in experimental animals

المؤلفون: D. I. Ionov, M. M. Fedorova, P. A. Galenko-Yaroshevsky, G. V. Sukoyan, N. V. Gongadze

المصدر: Кубанский научный медицинский вестник, Iss 5, Pp 69-74 (2015)

مصطلحات موضوعية: сердечная недостаточность, внутрисердечная гемодинамика, перегрузка сердца давлением, аденоцин®, левосимендан, врожденная иммунная система, цитокиновый профиль, ядерный фактор каппа в, heart failure, intracardiac hemodynamic, pressure overload, аdenocin®, levosimendan, innate immune system, cytokine system, nuclear factor-kb, Medicine

وصف الملف: electronic resource

Relation: https://ksma.elpub.ru/jour/article/view/392; https://doaj.org/toc/1608-6228; https://doaj.org/toc/2541-9544

URL الوصول: https://doaj.org/article/12d2f6c3a5f44e308978675dea243177

View record in DOAJ

12

Academic Journal

Периоперационное использование левосимендана в кардиохирургии

المؤلفون: В. В. Ломиворотов, А. А. Еременко, В. А. Бобошко, М. Н. Абубакиров

المصدر: Патология кровообращения и кардиохирургия, Vol 19, Iss 2, Pp 113-123 (2015)

مصطلحات موضوعية: Кардиохирургия, Аортокоронарное шунтирование, Операции на клапанах сердца, Синдром низкого сердечного выброса, Левосимендан, Surgery, RD1-811

وصف الملف: electronic resource

Relation: http://journalmeshalkin.ru/index.php/heartjournal/article/view/298; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

URL الوصول: https://doaj.org/article/a6fdd231f49c4ee9bfde8f3573ad7ee9

View record in DOAJ

13

Academic Journal

PREVENTION OF HEART FAILURE IN NON-CARDIAC SURGERY WITH THE LOWER EJECTION FRACTION OF LEFT VENTRICULAR: LEVOSIMENDAN OR ANESTHETIC CARDIOPROTECTION? (randomized multi-centered trial) ; ПРОФИЛАКТИКА СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ В НЕКАРДИАЛЬНОЙ ХИРУРГИИ У ПАЦИЕНТОВ СО СНИЖЕННОЙ ФРАКЦИЕЙ ИЗГНАНИЯ ЛЕВОГО ЖЕЛУДОЧКА: ЛЕВОСИМЕНДАН ИЛИ АНЕСТЕТИЧЕСКАЯ КАРДИОПРОТЕКЦИЯ? (рандомизированное мультицентровое исследование)

المؤلفون: V. V. Likhvantsev, D. N. Marchenko, O. A. Grebenchikov, Yu. V. Ubasev, T. S. Zabelina, S. S. Timoshin, В. В. Лихванцев, Д. Н. Марченко, О. А. Гребенчиков, Ю. В. Убасев, Т. С. Забелина, С. С. Тимошин

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 13, № 3 (2016); 74-79 ; Вестник анестезиологии и реаниматологии; Том 13, № 3 (2016); 74-79 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: некардиальная хирургия, levosimendan, heart failure, perioperative period, pre-operative preparation, non-cardiac surgery, левосимендан, сердечная недостаточность, периоперационный период, предоперационная подготовка

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/101/139; Ингаляционная индукция и поддержание анестезии / Под. ред. Лихванцева В. В. – М.: МиА, 2013. – 313 с.; Лихванцев В. В., Гребенчиков О. А., Шмелёва Е. А. и др. Анестетическое прекондиционирование: почему данные, полученные в эксперименте, не всегда подтверждаются в клинике? // Вестн. анестезиол. и реаниматол. – 2013. – № 4. – С. 9–16.; Убасев Ю. В., Скрипкин Ю. В., Забелина Т. С. и др. Инфузия левосимендана пожилым пациентам (60–75 лет) со сниженной ФИлж (; Aldrete J. A., Kroulik D. A. Postanesthetic Recovery Score // Anesth. Analg. – 1970. – Vol. 49, № 6. – P. 924–934.; Belhomme D., Peynet J., Louzy M. et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery // Circulation. – 1999. – Vol. 100, № 19. – P. 340–344.; Cromheecke S., Pepermans V., Hendrickx E. et al. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass // Anesth. Analg. – 2006. – Vol. 103, № 2. – P. 289–296.; de Hert S. et al. A comparison of volatile and non-volatile agents for cardioprotection during on-pump coronary surgery // Anaesthesia. – 2009. – Vol. 64. – P. 953–960.; Follath F., Cleland J. G., Just H. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial // Lancet. – 2002. – Vol. 360 (9328). – P. 196–202.; Kristensen S. D., Knuuti J., Saraste A. et al. ESC/ESA Guidelines on non– cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA) // Eur. J. Anaesthesiol. – 2014. – Vol. 31, № 10. – P. 517–573.; Landoni G., Augoustides J. G., Guarracino F. et al. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference // Acta Anaesth. Scand. – 2011. – Vol. 55. – P. 259–266.; Landoni G., Biondi-Zoccai G., Greco M. et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies // Crit. Care Med. – 2012. – Vol. 40, № 2. – P. 634–646.; Landoni G., Biondi-Zoccai G., Zangrillo A. et al. Desflurane and sevofluran in cardiac surgery: a meta-analysis of randomized clinical trials // J. Cardiothor. Vascular Anesthesia. – 2007. – Vol. 21, № 4. – P. 502–511.; Lim J. Y., Deo S. V., Rababa’h A. et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: A systematic review and meta-analysis // J. Card. Surg. – 2015. – Vol. 30, № 7. – P. 547–554.; Longrois D., Hoeft A., de Hert S. 2014 European Society of Cardiology/European Society of Anaesthesiology guidelines on non-cardiac surgery: cardiovascular assessment and management: A short explanatory statement from the European Society of Anaesthesiology members who participated in the European Task Force // Eur. J. Anaesthesiology. – 2014. – Vol. 31, № 10. – P. 513–516.; Moiseyev V. S., Poder P., Andrejevs N. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) // Eur. Heart J. – 2002. – Vol. 23, № 18. – P. 1422–1432.; Morelli A., Ertmer C., Pietropaoli P. et al. Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function? // Curr. Drug. Targets. – 2009. – Vol. 10, № 9. – P. 863–871.; Ponschab M., Hochmair N., Ghazwinian N. et al. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair // Eur. J. Anaesthesiol. – 2008. – Vol. 25, № 8. – P. 627–633.; Pearse R. M., Moreno R. P., Bauer P. et al. Mortality after surgery in Europe: a 7 day cohort study // Lancet. – 2012. – Vol. 380 (9847). – P. 1059–1065.; https://www.vair-journal.com/jour/article/view/101

الاتاحة: https://www.vair-journal.com/jour/article/view/101
https://doi.org/10.21292/2078-5658-2016-13-3-74-79

View record in BASE

14

Academic Journal

CARDIAC PROTECTIVE INOTROPIC THERAPY – OPPORTUNITIES AND PROSPECTIVE OF USING LEVOSIMENDAN IN CARDIAC SURGERY ; КАРДИОПРОТЕКТИВНАЯ ИНОТРОПНАЯ ТЕРАПИЯ – ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЛЕВОСИМЕНДАНА В КАРДИОХИРУРГИИ

المؤلفون: V. V. Pasyuga, V. V. Lomivorotov, A. A. Eremenko, В. В. Пасюга, В. В. Ломиворотов, А. А. Еременко

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 13, № 2 (2016); 70-77 ; Вестник анестезиологии и реаниматологии; Том 13, № 2 (2016); 70-77 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: сердечная недостаточность, levosimendan, cardiac surgery, heart failure, левосимендан, кардиохирургия

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/90/128; Григорьев E. В., Торопова Я. Г., Плотников Г. П. и др. Фармакологическая кардиопротекция при реперфузии изолированного сердца // Анестезиол. и реаниматол. – 2015. – № 2. – C. 12–16.; Еременко А. А., Колпаков П. Е., Бабаев М. А. и др. Применение левосимендана у кардиохирургических больных с хронической сердечной недостаточностью // Анестезиол. и реаниматол. – 2010. – № 2. – C. 24–27.; Ломиворотов В. В., Еременко А. А., Бобошко В. А. и др. Периоперационное использование левосимендана в кардиохирургии // Патология кровообращения и кардиохирургия. – 2015. – Т. 19, № 2. – С. 113–123.; Abraham W., Adams K., Fonarow G. et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medication: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) // J. Am. Coll. Cardiol. – 2005. – Vol. 46. – P. 57–64.; Adamopoulos S., Parissis J., Iliodromitis E. et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure // Am. J. Cardiol. – 2006. – Vol. 98. – P. 102–106.; Alvarez J., Baluja A., Selas S. et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study // Anaesth. Int. Care. – 2013. – Vol. 41. – P. 719–727.; Bassani R. A., Bassani J. W., Bers D. M. et al. Relaxation in ferret ventricular myocytes: role of the sarcolemmal Ca++ATPase // Pflugers Atchiv. – 1995. – Vol. 430. – P. 573–578.; Baysal A., Yanartas M., Dogukan M. et al. N. Levosimendan improves renal outcome in cardiac surgery: a randomised trial // J. Cardiothorac. Vasc. Anesth. – 2014. – Vol. 28. – P. 586–594.; Bers D. M., Measurment of Calcium transport in heart using modern approaches // New Horizons. – 1996. – Vol. 4. – P. 36–44.; Bers D. M. Calcium fluxes involved in control of cardiac myocyte contraction // Circ. Res. – 2000. – Vol. 87. – P. 275–281.; Bers D. M. Cardiac excitation-contraction coupling // Nature. – 2001. – Vol. 415. – P. 198–205.; Blinks J. R., Endoh M. Modification of myofibrillar responsiveness to Ca2+ as an inotropic mechanism // Circulation. – 1986. – Vol. 73. – Р. III85–III98.; Caimmi P. P., Kapetanakis E. I., Beggino C. et al. Management of acute cardiac failure by intracoronary administration of levosimendan // J. Cardiovasc. Pharmacol. TM. – 2011. – Vol. 58. – P. 246–253.; Cammarata G. A., Weil M. H., Sun S. et al. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 1083–1085.; Chen Q., Camara A. K., Rhodes S. S. et al. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts // Cardiovasc. Res. – 2003. – Vol. 59. – P. 912–925.; de Hert S. G., Lorsomradee S., vanden Eede H. et al. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction // J. Cardiothor. Vasc. Anesthesia. – 2008. – Vol 22, № 5. – P. 699–705.; Diaz M. E., Graham H. K., O’Neill S. C. et al. The control of carcoplasmic reticulum Ca2+content in cardiac muscle // Cell. Calcium. – 2005. – Vol. 38. – P. 391–396.; Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. – 2008. – Vol. 29. – P. 2388–2442.; du Toit E. F., Genis A., Opie L. H. et al. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart // Br. J. Pharmacol. – 2008. – Vol. 154. – P. 41–50.; Edes I., Kiss E., Kitada Y. et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart // Circ Res. – 1995. – Vol. 77. – P. 107–113.; Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses // Expert. Opin Pharmacother. – 2006. – Vol. 7. – P. 2179–2202.; Erdei N., Papp Z., Pollesello P. et al. The levosimendan metabolite OR–1896 elicits vasodilation by activating the K (ATP) and BK(Ca) channels in rat isolated arterioles // Br. J. Pharmacol. – 2006. – Vol. 148. – P. 696–702.; Fonarow G. C., Heywood J. T., Heidenreich P. A. et al. Temporal trends in clinical characteristics, treatments and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE) // Am. Heart J. – 2007. – Vol. 153. – P. 1021–1028.; Giannakoulas G., Giannoglou G., Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment // Am. J. Cardiol. – 2006. – Vol. 98. – P. 1123–1124.; Goetzenich A., Hatam N., Preuss S. et al. The role of hypoxia-inducible factor-1α and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes // Interact. Cardiovasc. Thorac. Surg. – 2014. – Vol. 18, № 3. – P. 321–328.; Greco T., Calabrò M. G., Covello R. D. et al. Bayesian network meta-analysis on the effect of inodilatory agents on mortality // Br. J. Anaesth. – 2015. – Vol. 114, № 5. – P. 746–756.; Grossini E., Caimmi P. P., Molinary C. et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig // J. Cardiovasc. Pharmacol. – 2006. – Vol. 46. – P. 333–342.; Haikala H., Nissinen E., Etemzadeh E. et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation // J. Cardiovasc. Pharmacol. – 1995. – Vol. 25. – P. 794–801.; Harrison R. W., Hasselblad V., Mehta R. H. et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 6. – P. 1224–1232.; Honisch A., Theuring N., Ebner B. et al. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition // Basic. Res. Cardiol. – 2009. – Vol. 105. – P. 155–167.; Jamali I. N., Kersten J. R., Pagel P. S. et al. Intracoronary levosimendan enhances contractile function of stunned myocardium // Anesth. Analg. – 1997. – Vol. 85. – P. 23–29.; Landoni G., Augoustides J. G., Guarracino F. et al. Mortality reduction in cardiac anesthesia and intensive care: Results of the Firs International Consensus Conference // Acta Anaesthesiol. Scand. – 2011. – Vol. 55. – P. 259–266.; Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies // Crit. Care Med. – 2012. – Vol. 40. – P. 634–646.; Landoni G., Mizzi A., Biondi-Zoccai G. et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials // J. Cardiothorac. Vascular Anesthesia. – 2010. – Vol 24, № 1. – P. 51–57.; Levin R., Degrange M., Del Mazo C. et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in high–risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass // Exp. Clin. Cardiol. – 2012. – Vol. 17. – P. 125–130.; Lochner A., Colesky F., Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium // Cardiovasc. Drugs Ther. – 2000. – Vol. 14. – P. 271–281.; Maharaj R., Metaxa V., Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials // Crit. Care. – 2011. – Vol. 15. – Р. R140.; Mebazaa A., Nieminen M. S., Packer M. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVED Randomized Trial // JAMA. – 2007. – Vol. 297. – P. 1883–1891.; Niu Z. Z., Wu S. M., Sun W. Y. et al. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis // J. Cardiovasc. Pharmacol. – 2014. – Vol. 63. – P. 107–112.; Packer M., Carver J. R., Rodeheffer R. J. at al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group // N. Engl. J. Med. – 1991. – Vol. 325. – P. 1468–1475.; Papp J. G., Pollesello P., Varro A. F. et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs // J. Cardiovasc. Pharmacol. Ther. – 2006. – Vol. 11. – P. 129–135.; Papp Z., Edes I., Fruhwald S. et al. Levosimendan: Molecular mechanisms and clinical implications consensus of experts on the mechanisms of action of levosimendan // Int. J. Cardiol. – 2012. – Vol. 159, № 2. – P. 82–87.; Parissis J. T., Adamopoulos S., Antoniades C. et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure // Am. J. Cardiol. – 2004. – Vol. 93. – P. 1309–1312.; Parissis J. T., Andreadou I., Markantonis S. L. et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure // Atherosclerosis. – 2007. – Vol. 195. – Р. e210–е215.; Parissis J. T., Karavidas A., Bistola V. et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure // Atherosclerosis. – 2008. – Vol. 197. – P. 278–282.; Robertson I. M., Sun Y. B., Li M. X. et al. A structural and functional perspective into the mechanism of Ca++-sensitizers that target the cardiac troponin complex // J. Mol. Cell. Cardiol. – 2010. – Vol. 49, № 6. – P. 1031–1041.; Sorsa T., Heikkinen S., Abbott M. B. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C // J. Biol. Chem. – 2001. – Vol. 276. – P. 9337–9343.; Sorsa T., Pollesello P., Rosevear P. R. et al., Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 1–8.; Sponga S., Ivanitskaia E., Potapov E. et al. Preoperative treatment with levosimendan in candidates for mechanical circulatory support // ASAIO J. – 2012. – Vol. 58. – P. 6–11.; Szilágyi S., Pollesello P., Levijoki J. et al. The effects of levosimendan and OR– 1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 67–74.; Theiss H. D., Grabmaier U., Kreissl N. et al. Preconditioning with levosimendan before implantation of left ventricular assist devices // Artif. Organs. – 2014. – Vol. 38. – P. 231–234.; Toller W., Algotsson L., Guarracino F. et al. Perioperative use of levosimendan: best practice in operative settings // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 2. – P. 361–366.; Toller W., Heringlake M., Guarracino F. et al. Preoperative and perioperative use of levosimendan in cardiac surgery European expert opinion // Int. J. Cardiology. – 2015. – Vol. 184. – P. 323–336.; Tritapepe L., de Santis V., Vitale D. et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery // Brit. J. Anaesthesia. – 2009. – Vol. 102, № 2. – P. 198–204.; https://www.vair-journal.com/jour/article/view/90

الاتاحة: https://www.vair-journal.com/jour/article/view/90
https://doi.org/10.21292/2078-5658-2016-13-2-70-77

View record in BASE

15

Academic Journal

IMPACT OF LEVOSIMENDAN ON RENAL FUNCTION IN COMPLEX TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE ; ВЛИЯНИЕ ЛЕВОСИМЕНДАНА НА ФУНКЦИЮ ПОЧЕК ПРИ КОМПЛЕКСНОЙ ТЕРАПИИ ОСТРОЙ ДЕКОМПЕНСАЦИИ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

المؤلفون: M. Lediakhova V., S. Nasonova N., I. Zhirov V., M. Andreevskaya V., R. Bogieva M., T. Uskach M., M. Saidova A., V. Masenko P., S. Tereshchenko N., М. Ледяхова В., С. Насонова Н., И. Жиров В., М. Андреевская В., Р. Богиева М., Т. Ускач М., М. Саидова А., В. Масенко П., С. Терещенко Н.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 14, No 2 (2018); 176-183 ; Рациональная Фармакотерапия в Кардиологии; Vol 14, No 2 (2018); 176-183 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2018-14-2

مصطلحات موضوعية: levosimendan, acute decompensated heart failure, glomerular filtration rate, creatinine, левосимендан, острая декомпенсация сердечной недостаточности, скорость клубочковой фильтрации, креатинин

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1645/1619; Терещенко С.Н., Жиров И.В., Насонова С.Н., и др. Острая декомпенсация сердечной недостаточности: состояние проблемы на 2016 г. Лечебное Дело. 2016;2:4-13.; Ватутин Н. Т., Тарадин Г. Г., Колесников В. С., Тараторина А. А., Зинкович М. И. Кардиоренальный синдром в интенсивной терапии. Журнал Сердечная Недостаточность. 2016;94(1):47-56. doi:10.18087/rhfj.2016.1.2130.; Pollesello P, Papp Z, Papp JG. Calcium sensitizers: what have we learned over the last 25 years? Int J Cardiol. 2016;203:543-8. doi:10.1016/j.ijcard.2015.10.240.; Pathak A, Lebrin M, VaccaroA et al. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotectiveeffects. J Clin Pharm Ther. 2013;38:341-9. doi:10.1111/jcpt.12067.; Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol. 2016;222:303-12. doi:10.1016/j.ijcard.2016.07.202.; Caimmi PP, Molinari C. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg. 2011;39:59-67. doi:10.1016/j.ejcts.2010.11.044.; Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol. 2007;150(7):851-61. doi:10.1038/sj.bjp.0707157.; Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50:257-63. doi:10.1097/FJC.0b013e3180986230.; Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431-5. doi:10.1007/s10557-007-6066-7.; Клинические рекомендации по диагностике и лечению хронической и острой сердечной недостаточности. Кардиологический Вестник. 2016,2:3-33.; Рекомендации по ведению пациентов с острой сердечной недостаточностью на догоспитальном и госпитальном этапах оказания медицинской помощи (часть 2). Неотложная Кардиология. 2017;13(1):34-59.; Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.; Packer M, Colucci W, Fisher L et al. REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1:103-111. doi:10.1016/j.jchf.2012.12.004.; Lilleberg J, Laine M, Palkama T et al. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007;9:75-82. doi:10.1016/j.ejheart.2006.04.012.; Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on betablockers in SURVIVE. Eur J Heart Fail. 2009;11:304-311. doi:10.1093/eurjhf/hfn045.; Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная недостаточность. 2013;81(7):379-472.; 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):147-239. doi:10.1016/j.jacc.2013.05.019.; Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure. 2015;17(6):544-58. doi:10.1002/ejhf.289.; Рекомендации по ведению пациентов с острой сердечной недостаточностью на догоспитальном и госпитальном этапах оказания медицинской помощи (часть 1). Неотложная Кардиология. 2016;12(4):33-61.; Рекомендации по ведению пациентов с острой сердечной недостаточностью на догоспитальном и госпитальном этапах оказания медицинской помощи (часть 3). Неотложная Кардиология. 2017;14(2):43-64.; Poelzl G, Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz. 2008,33:368-373. doi:10.1007/s00059-008-3051-2.; Russ MA, Prondzinsky R, Carter JM, et al. Right ventricular function in myocardial infarction complicated by cardiogenic shock: improvement with levosimendan. Crit Care Med. 2009;37:3017-23. doi:10.1097/CCM.0b013e3181b0314a.; Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328-35. doi:10.1097/CCM.0b013e31828e946a.; Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013;27(6):581-90. doi:10.1007/s10557-013-6485-6.; Zager RA, Johnson AC, Lund S, et al. Levosimendan protects against experimental endotoxemic acute renal failure. AJP-Renal Physiol. 2006;290(6):1453-62. doi:10.1152/ajprenal.00485.2005.; Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet. 2002;360:196-202. doi:10.1016/S0140-6736(02)09455-2.; Hou ZQ, Sun ZX, Su CY, Tan H et al. Shang Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31:108-114. doi:10.1111/1755-5922.12001.; Zorlu A, Yucel H, Yontar OC, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537-43. doi:10.1590/S0066782X2012005000048.; Rafouli-Stergiou P, Parissis JT, Farmakis D et al. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. J Cardiovasc Med (Hagerstown). 2015;1-3. doi:10.2459/JCM.0000000000000244.; https://www.rpcardio.com/jour/article/view/1645

الاتاحة: https://www.rpcardio.com/jour/article/view/1645
https://doi.org/10.20996/1819-6446-2018-14-2-176-183

View record in BASE

16

Academic Journal

Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью

المؤلفون: Ю. Б. Белоусов, Д. Ю. Белоусов

المصدر: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 1 (2006) ; Качественная клиническая практика; № 1 (2006) ; 2618-8473 ; 2588-0519

مصطلحات موضوعية: хроническая сердечная недостаточность, левосимендан

Relation: Stanton A. Therapeutic potential of rennin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003; 3: 389-94.; Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human rennin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005 Sep; 46: 569-76.; Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004 Dec; 15: 3126-33.; Pitt B., Remme W., Zannad F. et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and survival study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321.; Lee C.R., Watkins M.L., Patterson J.H. et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9-18.; Hauptman P.J., Zimmer C., Udelson J. et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 2005 Nov; 46: 609-14.; Spieker L.E., Mitrovic V., Noll G. et al. Acute hemodynamic and neurohumoral effects of selective ETa receptor blockade in patients with congestive heart failure: ET 003 Investigators. J Am Coll Cardiol 2000; 35: 1745-52.; Cheng J.W. Bosentan. Heart Dis 2003; 5: 161-9.; Ono K., Matsumori A. Endothelin antagonism with bosentan: current status and future perspectives. Cardiovascular Drug Review 2002; 20: 1-18.; Levin E.R., Kalman J., Samson W.K. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.; Bettencourt P. Brain natriuretic peptide (nesiritide) in the treatment of heart failure. Cardiovascular Drug Review 2002; 20: 27-36.; Rouleau J.L., Pfeffer M.A., Stewart D.J. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial. Lancet 2000; 356:1774.; Packer M., Califf R.M., Constam M.A. et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-6.; Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):68G-73G.; Haikala H., Nissinen E.,Etemadzadeh E. et all. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaction. J Cardiovasc Pharmacol; Ukkonen H., Saraste M., Akkila J. et al. Miocardial efficiency during levosimendan infusion in congestive heart failure. Clinical Pharmacology and Terapeutics 2000; 68: 522-531.; Kaheinen P., Polessello P., Levijoki J., Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium cannels. J Cardiovasc Pharmacol 2001; 37: 367-374.; Alvarez J., Taboada M., Rodriguez J. et al. Hemodynamic effects of levosimendan following cardiac surgery. Rev Esp Anestesiol Reanim 2005 Aug-Sep;52(7):389-94.; Maytin M., Colucci W.S. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):26G-31G.; Papp Z., Csapo K., Pollesello P. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005 Spring; 23 (1):71-98.; Parissis J.T., Panou F., Farmakis D. et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005 Aug 1;96(3):423-6.; Avgeropoulou C., Andreadou I., Markantonis-Kyroudis S. et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005 Aug;7(5):882-7.; Paraskevaidis I.A., Parissis J.T., Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents 2005 Jul; 3(3): 243-7.; Kivikko M., Antila S., Eha J. et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin. Pharmacol 2002; 42:43-51.; Kivikko M., Lehtonen L. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. Curr Pharm Des 2005;11(4):435-55.; Poder P., Eha J., Sundberg S. еt al. Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study. J Clin Pharmacol October 1, 2004; 44(10): 1143 - 1150.; Poder P., Eha J., Antila S. еt al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003 Sep-Nov; 17(5-6):451-8.; Antila S., Eha J., Heinpalu M. еt al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol. 1996; 49(6): 451-8.; Moiseyev V.S. et al. Safety and efficacy of a novel calcium sencitezer, Levosimendan, in patients with LVF due to an acute myocardial infarction. RUSSLAN. Eur Heart J 2002; 23: 1422-32.; Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J. 2003 May;4 Suppl 2:34S-38S.; Cleland J.G., Takala A., Apajasalo еt al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003 Jan;5(1):101-8.; Cleland J.G., Ghosh J., Freemantle N. еt al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004 Jun;6(4):501-8.; Mebazaa A., Barraud D., Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005 Sep 19;96(6A):74G-79G.; Faivre V., Kaskos H., Callebert J. et al.Cardiac and Renal Effects of Levosimendan, Arginine Vasopressin, and Norepinephrine in Lipopolysaccharide-treated Rabbits.Anesthesiology 2005 Sep;103(3):514-521.; Morelli A., De Castro S., Teboul J.L. et all. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005 May;31(5):638-44.; Follath F., Franco F., Cardoso J.S. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005 Sep 19;96(6A):80G-5G.; Garcia-Gonzalez M.J., Dominguez-Rodriguez A., Ferrer-Hita J.J. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005 Jun;45(6):704-8.; Zobel C., Reuter H., Schwinger R.H. Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan. Med Klin (Munich) 2004 Dec 15;99(12):742-6.; Siirila-Waris K., Suojaranta-Ylinen R., Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005 Jun;19(3):345-9.; Wang J., Weil M.H., Tang W. et al. Levosimendan improves postresuscitation myocardial dysfunction after beta-adrenergic blockade.J Lab Clin Med. 2005 Sep;146(3):179-83.; Verre M., Bossio F., Durante M. et al. Use of levosimendan after cardiac arrest by ventricular fibrillation: a case report. Clin Ter 2005 May-Jun;156(3):111-4.; Kasikcioglu H.A., Unal S., Tartan Z. et al. Effects of levosimendan on left ventricular functional remodeling and exercise intolerance: a tissue Doppler study. J Int Med Res 2005 Jul-Aug; 33(4):397-405.; Белоусов Ю.Б., Белоусов Д.Ю., Григорьев В.Ю., Бекетов А.С., Медников О.И. Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью // Сердечная недостаточность, №1 2006 г. стр. том 7, №1 (35), 2006, стр.32-38.; Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized, doubleblind study. Lancet 2002;360(9328):196–202.; WHO Commission on Macroeconomics and Health. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO, 2001; Госкомстат РФ, 2001-2004 гг., www.gks.ru; Willens HJ, Chakko S, Simmons J, Kessler KM. Cost-effectiveness in clinical cardiology. Part 1: coronary artery disease and congestive heart failure. Chest 1996;109:1359 –69.; Ардашев А.В., Желяков Е.Г. Применение имплантируемых кардиовертеров-дефибрилляторов для профилактики внезапной сердечной смерти //Российский кардиологический журнал, 2004 г., №3 стр.35-41; Cleland JGF. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998;19(Suppl P):P32 –P39.; Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999;83:890 –6.; Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. PharmacoEconomics 2001;19:901 – 16.; Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in heart failure. Am J Med 2001;110(Suppl 7A):74S–80S.; Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytictherapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418 –24.; Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred lifesaving interventions and their cost-effectiveness. Risk Anal 1995;15:369 –90.; Nainggolan L. CASINO results: should docs gamble on Levosimendan. www.theHeart.org.; Моисеев В.С., Poder P., Андреев Н.А., Руда М.Я., Голиков А.П., Лазебник Л.Б., Кобалава Ж.Д., Lehtonen L., Laine Т., Nieminen М., Lie К. от имени участников исследования RUSSLAN. Безопасность и эффективность Левосимендана у больных левожелудочковой недостаточностью при остром инфаркте миокарда. Рандомизированное двойное слепое плацебоконтролируемое исследование (RUSSLAN) // Клин. фармакол. тер., 2004, 13 (4), стр. 32-38.; The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001. 345(7): p. 494-502.; The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med 2000, 342: 145–153.; The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357; https://www.clinvest.ru/jour/article/view/321

الاتاحة: https://www.clinvest.ru/jour/article/view/321

View record in BASE

17

Academic Journal

Фармакоэкономический анализ применения левосимендана у больных с тяжёлой декомпенсированной хронической сердечной недостаточностью

المصدر: Качественная клиническая практика, Vol 0, Iss 1 (2018)

مصطلحات موضوعية: фармакоэкономика, левосимендан, хроническая сердечная недостаточность, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Relation: https://www.clinvest.ru/jour/article/view/321; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473; https://doaj.org/article/4edb5bc6db18490e84cba0e10d61e933

الاتاحة: https://doaj.org/article/4edb5bc6db18490e84cba0e10d61e933

View record in BASE

18

Academic Journal

Perioperative Predictors of Unfavorable Outcome of Vascular Surgery ; Периоперационные предикторы неблагоприятного исхода сосудистых вмешательств

المؤلفون: Viktor V. Moroz, Denis N. Marchenko, Yury V. Skripkin, Taniana S. Zabelina, Alexey M. Ovezov, Valery V. Likhvantsev, В. В. Мороз, Д. Н. Марченко, Ю. В. Скрипкин, Т. С. Забелина, А. М. Овезов, В. В. Лихванцев

المصدر: General Reanimatology; Том 13, № 3 (2017); 6-12 ; Общая реаниматология; Том 13, № 3 (2017); 6-12 ; 2411-7110 ; 1813-9779 ; 10.15360/1813-9779-2017-3

مصطلحات موضوعية: тропонин, postoperative mortality, levosimendan, anesthetic cardioprotection, troponin, послеоперационная летальность, левосимендан, анестетическая кардиопротекция

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/1588/1090; https://www.reanimatology.com/rmt/article/view/1588/1125; Devereaux P.J., Sessler D.I. Cardiac complications in patients undergoing major noncardiac surgery. N. Engl. J. Med. 2015; 373 (23): 2258–2269. https://doi.org/10.1056/NEJMra1502824. PMID: 26630144; Botto F., Alonso Coello P., Chan M.T., Villar J.C., Xavier D., Srinathan S., Guyatt G., Cruz P., Graham M., Wang C.Y., Berwanger O., Pearse R.M., Biccard B.M., Abraham V., Malaga G., Hillis G.S., Rodseth R.N., Cook D., Polanczyk C.A., Szczeklik W., Sessler D.I., Sheth T., Ackland G.L., Leuwer M., Garg A.X., Lemanach Y., Pettit S., Heels Ansdell D., Luratibuse G., Walsh M., Sapsford R., Schünemann H.J., Kurz A., Thomas S., Mrkobrada M., Thabane L., Gerstein H., Paniagua P., Nagele P., Raina P., Yusuf S., Devereaux P.J., Devereaux P.J., Sessler D.I., Walsh M., Guyatt G., McQueen M.J., Bhandari M., Cook D., Bosch J., Buckley N., Yusuf S., Chow C.K., Hillis G.S., Halliwell R., Li S., Lee V.W., Mooney J., Polanczyk C.A., Furtado M.V., Berwanger O., Suzumura E., Santucci E., Leite K., Santo J.A., Jardim C.A., Cavalcanti A.B., Guimaraes H.P., Jacka M.J., Graham M., McAlister F., McMurtry S., Townsend D., Pannu N., Bagshaw S., Bessissow A., Bhandari M., Duceppe E., Eikelboom J., Ganame J., Hankinson J., Hill S., Jolly S., Lamy A., Ling E., Magloire P., Pare G., Reddy D., Szalay D., Tittley J., Weitz J., Whitlock R., Darvish Kazim S., Debeer J., Kavsak P., Kearon C., Mizera R., O’Donnell M., McQueen M., Pinthus J., Ribas S., Simunovic M., Tandon V., Vanhelder T., Winemaker M., Gerstein H., McDonald S., O’Bryne P., Patel A., Paul J., Punthakee Z., Raymer K., Salehian O., Spencer F., Walter S., Worster A., Adili A., Clase C., Cook D., Crowther M., Douketis J., Gangji A., Jackson P., Lim W., Lovrics P., Mazzadi S., Orovan W., Rudkowski J., Soth M., Tiboni M., Acedillo R., Garg A., Hildebrand A., Lam N., Macneil D., Mrkobrada M., Roshanov P.S., Srinathan S.K., Ramsey C., John P.S., Thorlacius L., Siddiqui F.S., Grocott H.P., McKay A., Lee T.W., Amadeo R., Funk D., McDonald H., Zacharias J., Villar J.C., Cortés O.L., Chaparro M.S., Vásquez S., Castañeda A., Ferreira S., Coriat P., Monneret D., Goarin J.P., Esteve C.I., Royer C., Daas G., Chan M.T., Choi G.Y., Gin T., Lit L.C., Xavier D., Sigamani A., Faruqui A., Dhanpal R., Almeida S., Cherian J., Furruqh S., Abraham V., Afzal L., George P., Mala S., Schünemann H., Muti P., Vizza E., Wang C.Y., Ong G.S., Mansor M., Tan A.S., Shariffuddin I.I., Vasanthan V., Hashim N.H., Undok A.W., Ki U., Lai H.Y., Ahmad W.A., Razack A.H., Malaga G., Valderrama Victoria V., Loza Herrera J.D., De Los Angeles Lazo M., Rotta Rotta A., Szczeklik W., Sokolowska B., Musial J., Gorka J., Iwaszczuk P., Kozka M., Chwala M., Raczek M., Mrowiecki T., Kaczmarek B., Biccard B., Cassimjee H., Gopalan D., Kisten T., Mugabi A., Naidoo P., Naidoo R., Rodseth R., Skinner D., Torborg A., Paniagua P., Urrutia G., Maestre M.L., Santaló M., Gonzalez R., Font A., Martínez C., Pelaez X., De Antonio M., Villamor J.M., García J.A., Ferré M.J., Popova E., Alonso Coello P., Garutti I., Cruz P., Fernández C., Palencia M., Díaz S., Del Castillo T., Varela A., de Miguel A., Muñoz M., Piñeiro P., Cusati G., Del Barrio M., Membrillo M.J., Orozco D., Reyes F., Sapsford R.J., Barth J., Scott J., Hall A., Howell S., Lobley M., Woods J., Howard S., Fletcher J., Dewhirst N., Williams C., Rushton A., Welters I., Leuwer M., Pearse R., Ackland G., Khan A., Niebrzegowska E., Benton S., Wragg A., Archbold A., Smith A., McAlees E., Ramballi C., Macdonald N., Januszewska M., Stephens R., Reyes A., Paredes L.G., Sultan P., Cain D., Whittle J., Del Arroyo A.G., Sessler D.I., Kurz A., Sun Z., Finnegan P.S., Egan C., Honar H., Shahinyan A., Panjasawatwong K., Fu A.Y., Wang S., Reineks E., Nagele P., Blood J., Kalin M., Gibson D., Wildes T.; Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Writing Group, on behalf of The Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Investigators; Appendix 1. The Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) Study Investigators Writing Group; Appendix 2. The Vascular events In noncardiac Surgery patIents cOhort evaluatioN Operations Committee; Vascular events In noncardiac Surgery patIents cOhort evaluatioN VISION Study Investigators. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study estab- lishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014; 120 (3): 564–578. https://doi.org/10.1097/ ALN.0000000000000113. PMID: 24534856; Landesberg G., Beattie W.S., Mosseri M., Jaffe A.S., Alpert J.S. Perioperative myocardial infarction. Circulation. 2009; 119 (22): 2936–2944. https://doi.org/10.1161/CIRCULATIONAHA.108.828228. PMID: 19506125; Badner N.H., Knill R.L., Brown J.E., Novick T.V., Gelb A.W. Myocardial infarction after noncardiac surgery. Anesthesiology. 1998; 88 (3): 572–578. https://doi.org/10.1097/00000542- 199803000-00005. PMID: 9523798; Devereaux P.J., Xavier D., Pogue J., Guyatt G., Sigamani A., Garutti I., Leslie K., Rao Melacini P., Chrolavicius S., Yang H., Macdonald C., Avezum A., Lanthier L., Hu W., Yusuf S.; POISE (PeriOperative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann. Intern. Med. 2011; 154 (8): 523–528. https://doi.org/10.7326/0003-4819-154-8-201104190-00003.PMID: 21502650; Лихванцев В.В., Убасев Ю.В., Скрипкин Ю.В., Забелина Т.С., Сунгу ров В.А., Ломиворотов В.В., Марченко Д.Н. Предоперационная про- филактика сердечной недостаточности в некардиальной хирургии. Общая реаниматология. 2016; 12 (3): 48–61. https://doi.org/ 10.15360/1813-9779-2016-3-48-61; Hammill B.G., Curtis L.H., Bennett Guerrero E., O’Connor C.M., Jollis J.G., Schulman K.A., Hernandez A.F. Impact of heart failure on patients under- going major noncardiac surgery. Anesthesiology. 2008; 108 (4): 559–567. https://doi.org/10.1097/ALN.0b013e31816725ef. PMID: 18362586; van Diepen S., Bakal J.A., McAlister F.A., Ezekowitz J.A. Mortality and readmission of patients with heart failure, atrial fibrillation, or coro- nary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation. 2011; 124 (3): 289–296. https://doi.org/ 10.1161/CIRCULATIONAHA.110.011130.PMID: 21709059; Kristensen S.D., Knuuti J., Saraste A., Anker S., Bøtker H.E., Hert S.D., Ford I., Gonzalez Juanatey J.R., Gorenek B., Heyndrickx G.R., Hoeft A., Huber K., Iung B., Kjeldsen K.P., Longrois D., Lüscher T.F., Pierard L., Pocock S., Price S., Roffi M., Sirnes P.A., Sousa Uva M., Voudris V., Funck Brentano C.; Authors/Task Force Members. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and man- agement: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur. Heart J. 2014; 35 (35): 2383–2431. https://doi.org/10.1093/eurheartj/ ehu282. PMID: 25086026; Лихванцев В.В., Марченко Д.Н., Гребенчиков О.А., Убасев Ю.В., Забелина Т.С., Тимошин С.С. Профилактика сердечной недостаточности в некардиальной хирургии у пациентов со сниженной фракцией изгнания левого желудочка: левосимендан или анестетическая кардиопротекция? (рандомизированное мультицентровое исследование). Вестн. анестезиологии и реаниматологии. 2016; 13 (3): 74–79. https://doi.org/ 10.21292/2075-1230-2016-13-3-74-80; Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators, Devereaux P.J., Chan M.T., Alonso Coello P., Walsh M., Berwanger O., Villar J.C., Wang C.Y., Garutti R.I., Jacka M.J., Sigamani A., Srinathan S., Biccard B.M., Chow C.K., Abraham V., Tiboni M., Pettit S., Szczeklik W., LuratiBuse G., Botto F., Guyatt G., Heels Ansdell D., Sessler D.I., Thorlund K., Garg A.X., Mrkobrada M., Thomas S., Rodseth R.N., Pearse R.M., Thabane L., McQueen M.J., VanHelder T., Bhandari M., Bosch J., Kurz A., Polanczyk C., Malaga G., Nagele P., LeManach Y., Leuwer M., Yusuf S. Association between post- operative troponin levels and 30-day mortality among patients under- going noncardiac surgery. JAMA. 2012; 307 (21): 2296–2304. https://doi.org/10.1001/jama.2012.5502. PMID: 22706835; Корниенко А.Н., Добрушина О.Р., Зинина Е.П. Профилактика кардиальных осложнений внесердечных операций. Общая реаниматология. 2011; 7 (5): 57–66. http://dx.doi.org/10.15360/1813-9779-2011-5-57; https://www.reanimatology.com/rmt/article/view/1588

الاتاحة: https://www.reanimatology.com/rmt/article/view/1588
https://doi.org/10.15360/1813-9779-2017-3-6-12

View record in BASE

19

Academic Journal

NEW POSSIBILITIES OF ECHOCARDIOGRAPHIC METHOD IN EVALUATION OF CYCLE ANALYSIS OF CARDIAC MECHANICS IN CARDIOGRAPHIC PATIENTS ; Новые возможности эхокардиографического метода в оценке поциклового анализа механики сердца у кардиохирургических больных

المؤلفون: V. SANDRIKOV A., T. KULAGINA Y., E. VAN Y., E. BEREZINA V., A. EREMENKOV A., M. BABAEV A., В. САНДРИКОВ А., Т. КУЛАГИНА Ю., Е. ВАН Ю., Е. БЕРЕЗИНА В., А. ЕРЕМЕНКО А., М. БАБАЕВ А.

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2016); 90-94 ; Медицинский Совет; № 13 (2016); 90-94 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-13

مصطلحات موضوعية: echocardiography, myocardium biomechanics, myocardium displacement speed, “Flow-Volume” chart, levosimendan, эхокардиография, биомеханика миокарда, скорость смещения миокарда, диаграмма «поток – объем», левосимендан

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1369/1328; Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 81(7): 379-472. / National guidelines PRAS, RKO and РНМОТ for the diagnosis and treatment of chronic heart failure (fourth revision). Journal of Cardiac Failure, 2013, 81(7): 379-472.; Еременко А.А., Бабаев М.А., Фоминых М.В., Колпаков П.Е., Федулова С.В. Использование левосимендана для оценки резервных возмож ностей миокарда у кардиохирургических пациентов с сердечной недостаточностью. Кардиология и сердечно-сосудистая хирургия, 2013, 1: 81-86. / Eremenko А.А., Babaev M.А., Fominykh M.V., Kolpakov P.E., Fedulova S.V. Use levosimendan to assess the reserve capacity of cardiac infarction in patients with heart failure. Cardiology and cardiovascular surgery, 2013, 1: 81-86.; Лобачева Г.В. Абдугаппаров Б.А., Абасов Ф.Х. Случаи успешного лечения сердечной недостаточности после кардиохирургических вмешательств. Анестезиология и реаниматология, 2013, 5: 56-57. / Lobacheva G.V., Abdugapparov B.A., Abasov F.H. Cases of successful treatment of heart failure after cardiac surgeries. Anesteziologiya and reanimatologiya, 2013, 5: 56-57.; Сандриков В.А., Кулагина Т.Ю., Гаврилов В.А., Архипов И.В. Патент на изобретение №2354301. Способ диагностики недостаточности сократительной функции миокарда от 10.10.2007. / Sandrikov V.A., Kulagina T.Yu., Gavrilov A. V., Arkhipov I. V. Medical patent №2354301. A method to diagnose heart pump failure 10.10.2007.; Сандриков В.А., Кулагина Т.Ю., Ван Е.Ю., Дземешкевич С.Л., Гаврилов А.В., Архипов И.В. Диаграмма «поток-объем» у пациентов с аортальным стенозом (сообщение 1). Ультразвуко вая и функциональная диагностика, 2010, 6: 56-64. / Sandrikov V.A., Kulagina T. Yu., Van Ye. Yu., Dzemeshkevich S.L., Gavrilov A. V., Arkhipov I. V. «Flow-volume» diagram in patients with aortic stenosis. Ultrasound functional diagnostics, 2010, 6: 56-64.; Сандриков В.А., Кулагина Т.Ю., Ван Е.Ю., Березина Е.В. Диастолическая дисфункция миокарда у пациентов с аортальной недостаточностью. Диаграмма «поток – объем». Ультразвуковая и функциональная диагностика, 2012, 2: 84-93. / Sandrikov V.A., Kulagina T. Yu., Van Ye. Yu., Berezina E.V. Myocardial Diastolic Dysfunction in Patients with Aortic Insufficiency. Flow–volume Loop. Ultrasound functional diagnostics. 2012, 2: 84-94.; Константинов Б.А., Сандриков В.А., Кулагина Т.Ю. Деформация миокарда и насосная функция сердца. 1-е издание. М.: ООО «Фирма СТРОМ», 2006, 304с.: ил. / / Konstantinov B.A., Sandrikov V.A., Kulagina T.Yu. Myocardial strain and heart pump function. 1-st edition. М.: LLC «Firma STROM», 2006, 304 p. 8. Opie L. Heart physiology. From cell to circulation. Philadelphia. 2004, 648 p.; https://www.med-sovet.pro/jour/article/view/1369

الاتاحة: https://www.med-sovet.pro/jour/article/view/1369
https://doi.org/10.21518/2079-701X-2016-13-90-94

View record in BASE

20

Academic Journal

Preoperative Prevention of Heart Failure in Noncardiac Surgery ; ПРЕДОПЕРАЦИОННАЯ ПРОФИЛАКТИКА СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ В НЕКАРДИАЛЬНОЙ ХИРУРГИИ

المؤلفون: V. V. Likhvantsev, Yu. V. Ubasev, Yu. V. Skripkin, T. S. Zabelina, V. A. Sungurov, V. V. Lomivorotov, D. N. Marchenko, В. В. Лихванцев, Ю. В. Убасев, Ю. В. Скрипкин, Т. С. Забелина, В. А. Сунгуров, В. В. Ломиворотов, Д. Н. Марченко

المصدر: General Reanimatology; Том 12, № 3 (2016); 48-61 ; Общая реаниматология; Том 12, № 3 (2016); 48-61 ; 2411-7110 ; 1813-9779 ; 10.15360/1813-9779-2016-3

مصطلحات موضوعية: некардиальная хирургия, levosimendan, heart failure, NTproBNP, noncardiac surgery, левосимендан, сердечная недостаточность

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/1530/1022; https://www.reanimatology.com/rmt/article/view/1530/1036; Pearse R.M., Moreno R.P., Bauer P., Pelosi P., Metnitz P., Spies C., Vallet B., Vincent J.L., Hoeft A., Rhodes A.; European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study. Lancet. 2012; 380 (9847): 1059—1065. http://dx.doi.org/10.1016/S01406736(12)611489. PMID: 22998715; Корниенко А.Н., Добрушина О.Р., Зинина Е.П. Профилактика кардиальных осложнений внесердечных операций. Общая реаниматология. 2011; 7 (5): 57—66. http://dx.doi.org/10.15360/181397792011557; Лихванцев В.В., Скрипкин Ю.В., Гребенчиков О.А. Изучение клинической значимости анестетического прекондиционирования (от крытая база данных). Общая реаниматология. 2014; 10 (4): 82—85. http://dx.doi.org/10.15360/18139779201448285; Авдейкин С.Н., Тюрин И.Н., Карпун Н.А. Оптимизация мониторинга гемодинамики больных с тяжелой внебольничной пневмонией. Общая реаниматология. 2015; 11 (2): 18—24. http://dx.doi.org/10.15360/18139779201521824; Lilleberg J., Nieminen M.S., Akkila J., Heikkilä L., Kuitunen A., Lehtonen L., Verkkala K., Mattila S., Salmenperд M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur. Heart J. 1998; 19 (4): 660—668. http://dx.doi.org/10.1053/euhj.1997.0806. PMID: 9597417; Tritapepe L., De Santis V., Vitale D., Guarracino F., Pellegrini F., Pietropaoli P., Singer M. Levosimendan pretreatment improves out comes in patients undergoing coronary artery bypass graft surgery. Br. J. Anaesth. 2009; 102 (2): 198—204. http://dx.doi.org/10.1093/ bja/aen367. PMID: 19151048; Eriksson H.I., Jalonen J.R., Heikkinen L.O., Kivikko M., Laine M., Leino K.A., Kuitunen A.H., Kuttila K.T., Peräkylä T.K., Sarapohja T., SuojarantaYlinen R.T., Valtonen M., Salmenperä M.T. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergo ing coronary artery bypass grafting with impaired left ventricular function. Ann. Thorac. Surg. 2009; 87 (2): 448—454. http://dx.doi.org/10.1016/j.athoracsur.2008.10.029. PMID: 19161758; Lahtinen P., Pitkänen O., Pölönen P., Turpeinen A., Kiviniemi V., Uusaro A. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo — controlled trial. Crit. Care Med. 2011; 39 (10): 2263—2270. http://dx.doi.org/10.1097/CCM.0b013e3182227b97.PMID: 21666445; Parissis J.T., Paraskevaidis I., Bistola V., Farmakis D., Panou F., Kourea K., Nikolaou M., Filippatos G., Kremastinos D. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am. J. Cardiol. 2006; 98 (11): 1489—1492. http://dx.doi.org/10.1016/j.amjcard.2006.06.052. PMID: 17126656; De Hert S.G., Lorsomradee S., Cromheecke S., Van der Linden P.J. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth. Analg. 2007; 104 (4): 766—773. http://dx.doi.org/10.1213/01.ane.0000256863.92050.d3. PMID: 17377079; Моисеев В.С., Poder P., Андреев Н.А., Руда М.Я., Голиков А.П., Лазебник Л.Б., Кобалава Ж.Д., Lehtonen L., Laine Т., Nieminen М., Lie К. Безопасность и эффективность левосимендана у больных левожелудочковой недостаточностью при остром инфаркте миокарда. Рандомизированное двойное слепое плацебоконтролируемое исследование (RUSSLAN). Клин. фармакология и терапия. 2004; 13(4): 32—38.; Lomivorotov V.V., Boboshko V.A., Efremov S.M., Kornilov I.A., Chernyavskiy A.M., Lomivorotov V.N., Knazkova L.G., Karaskov A.M. Levosimendan versus an intraaortic balloon pump in highrisk cardiac patients. J. Cardiothorac. Vasc. Anesth. 2012; 26 (4): 596—603. http://dx.doi.org/10.1053/j.jvca.2011.09.006. PMID: 22051419; Toller W., Heringlake M., Guarracino F., Algotsson L., Alvarez J., Argyriadou H., BenGal T., C…erný V., Cholley B., Eremenko A., Guerrero Orriach J.L., Järvelä K., Karanovic N., Kivikko M., Lahtinen P., Lomivorotov V., Mehta R.H., Mušiº Š., Pollesello P., Rex S., Riha H., Rudiger A., Salmenperä M., Szudi L., Tritapepe L., Wyncoll D., Öwall A. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int. J. Cardiol. 2015; 184: 323—336. http://dx.doi.org/10.1016/j.ijcard.2015.02.022. PMID: 25734940; Harrison R.W., Hasselblad V., Mehta R.H., Levin R., Harrington R.A., Alexander J.H. Effect of levosimendan on survival and adverse events after cardiac surgery: a metaanalysis. J. Cardiothorac. Vasc. Anesth. 2013; 27 (6): 1224—1232. http://dx.doi.org/10.1053/j.jvca.2013. 03.027. PMID: 24050857; Landoni G., BiondiZoccai G., Greco M., Greco T., Bignami E., Morelli A., Guarracino F., Zangrillo A. Effects of levosimendan on mortality and hospitalization. A metaanalysis of randomized controlled studies. Crit. Care Med. 2012; 40 (2): 634—646. http://dx.doi.org/10.1097/CCM.0b013e318232962a. PMID: 21963578; Levin R.L., Degrange M.A., Porcile R., Salvagio F., Blanco N., Botbol A.L., Tanus E., del Mazo C.D. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome. Rev. Esp. Cardiol. 2008; 61 (5): 471—479. http://dx.doi.org/10.1016/S18855857(08)601607. PMID: 18462650; Katsaragakis S., Kapralou A., Markogiannakis H., Kofinas G., Theodoraki E.M., Larentzakis A., Menenakos E., Theodorou D. Preoperative levosimendan in heart failure patients undergoing non cardiac surgery. Neth. J. Med. 2008; 66 (4): 154—159. PMID: 18424862; Leppikangas H., Tenhunen J.J., Lindgren L., Salenius J.P., Ruokonen E. Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal—arterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol. Scand. 2008; 52 (6): 785— 792. http://dx.doi.org/10.1111/j.13996576.2008.01659.x. PMID: 18477074; Slawsky M.T., Colucci W.S., Gottlieb S.S., Greenberg B.H., Haeusslein E., Hare J., Hutchins S., Leier C.V., LeJemtel T.H., Loh E., Nicklas J., Ogilby D., Singh B.N., Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000; 102 (18): 2222—2227. http://dx.doi.org/10.1161/01.CIR.102.18.2222. PMID: 11056096; Follath F., Cleland J.G., Just H., Papp J.G., Scholz H., Peuhkurinen K., Harjola V.P., Mitrovic V., Abdalla M., Sandell E.P., Lehtonen L.; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): a randomised doubleblind trial. Lancet. 2002; 360(9328): 196—202. http://dx.doi.org/10.1016/S01406736(02)094552. PMID: 12133653; Packer M., Colucci W., Fisher L., Massie B.M., Teerlink J.R., Young J., Padley R.J., Thakkar R., DelgadoHerrera L., Salon J., Garratt C., Huang B., Sarapohja T.; REVIVE Heart Failure Study Group. Effect of levosi mendan on the shortterm clinical course of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. Heart Fail. 2013; 1 (2): 103—111. http://dx.doi.org/10.1016/j.jchf.2012.12.004. PMID: 24621834; Nieminen M.S., Brutsaert D., Dickstein K., Drexler H., Follath F., Harjola V.P., Hochadel M., Komajda M., Lassus J., LopezSendon J.L., Ponikowski P., Tavazzi L.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart J. 2006; 27 (22): 2725—2736. http://dx.doi.org/10.1093/eurheartj/ehl193. PMID: 17000631; Мороз В.В., Добрушина О.Р., Стрельникова Е.П., Корниенко А.Н., Зинина Е.П. Предикторы кардиальных осложнений операций на органах брюшной полости и малого таза у больных пожилого и старческого возраста. Общая реаниматология. 2011; 7 (5): 26—31. http://dx.doi.org/10.15360/181397792011526; Козлов И.А., Кричевский Л.А., Шумаков Д.В., Харламова И.Е., Ермакова И.П., Никонова Т.Ю., Завгородний В.Н. Плазменный уровень неактивной части предшественника Втипа натрийуретического пептида как предиктора функции сердца при операциях с искусственным кровообращением. Анестезиология и реаниматология. 2006; 3: 30—33. PMID: 16889209; Мороз В.В., Никифоров Ю.В., Кричевский Л.А., Асеев В.М., Гусева О.Г., Буржунова М.Г., Рыбаков В.Ю. Значение сердечного пептида NTproBNP в оценке риска реваскуляризации миокарда у больных со сниженной фракцией изгнания левого желудочка. Общая реаниматология. 2010; 6 (2): 38—42. http://dx.doi.org/10.15360/1813 97792010238; Ломиворотов В.В., Бобошко В.А., Бобошко А.В., Чернявский А.М., Николаев Д.А., Корнилов И.А., Шилова А.Н., Ломиворотов В.Н. Использование интраоперационной внутриаортальной баллонной контрпульсации и левосимендана в кардиохирургии. Кардиология и сердечнососудистая хирургия. 2013; 6 (2): 75—81.; White P.F., Song D. New criteria for fasttracking after outpatient anesthesia: a comparison with the modified Aldrete’s scoring system. Anesth. Analg. 1999; 88 (5): 1069—1072. http://dx.doi.org/10.1213/0000053919990500000018. PMID: 10320170; https://www.reanimatology.com/rmt/article/view/1530

الاتاحة: https://www.reanimatology.com/rmt/article/view/1530
https://doi.org/10.15360/1813-9779-2016-3-48-61

View record in BASE

تنقيح النتائج